Abstract: PUB231
Identifying Global Awareness of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) through Google Search Trend Analysis
Session Information
Category: Diversity and Equity in Kidney Health
- 900 Diversity and Equity in Kidney Health
Authors
- Fichadiya, Harshil, Mayo Clinic Minnesota, Rochester, Minnesota, United States
- Patel, Vraj, Canton Medical Education Foundation, Canton, Ohio, United States
- Cheungpasitporn, Wisit, Mayo Clinic Minnesota, Rochester, Minnesota, United States
- Craici, Iasmina, Mayo Clinic Minnesota, Rochester, Minnesota, United States
Background
GLP-1 RA initially introduced as anti-glycemic agents are now found beneficial in HF, ASCVD & CKD and most popularly in treatment of Obesity. This has made GLP1RA a popular choice among patients with a higher BMI and diabetes requiring a kidney transplant. We performed a google trend analysis of GLP1RA related google search since 2004 and assessed the trend of this search overtime and in different areas of the World. This may be an indirect measure of public awareness, availability, and utility of these drugs in different regions globally.
Methods
A retrospective analysis of Google Trends was conducted for the term “GLP-1 Receptor Agonist” from its inception in 2004 until May 21, 2024. Search trends were assessed over time as well as per nation.
Results
Search started trending up from 2020 & increased exponentially from September 2023. The number of google searches per region have been distributed in different shades of blue in Fig 1 with the darkest shade representing region with the highest number of searches and the lightest shade representing region with the lowest number. Grey represents areas with lack of enough data for the term. Highest search rates were seen in Denmark, USA, South Korea and lowest search rates were seen in Russia, Vietnam and Turkey. Many Africian, some Eastern European and some central Asian countries did not have enough data to compute a search number. Search trends more or less corelated with search trends of obesity and to a lesser extent to diabetes and CKD.
Conclusion
GLP1RA are found to be beneficial in treatment of multiple disorders like HF, obesity, diabetes and CKD which are major contributors to morbidity and mortality in the current time. Equal awarness, distribution and access to these drugs is essential from a global health perspective. Map in Fig 1 helps us identify area with low awarness (as indicated indirectly by low google search trend) such that targeted efforts can be channeled to these areas to improve access and awareness. Some common causes of low awarness maybe socioeconomic disparities, high cost & lack of medical literature access and efforts should be made to mitigate these